The Sydney Morning Herald: Moderna COVID-19 vaccine booster dose ‘appears protective against Omicron’
Following laboratory testing, data shows that whilst a two-dose primary course of the Spikevax (Moderna) vaccine resulted in a low generation of neutralising antibodies against the Omicron variant, a booster dose provided a 37-fold increase in neutralising antibodies.
For more information on these findings refer to the full article via the link below:
Moderna COVID-19 vaccine booster dose ‘appears protective against Omicron’
Raising Children Network - COVID-19 vaccination and children: 5-11 years
Immunising children against COVID-19 ensures stronger, longer-lasting protection than infection does. To build the best immunity, ATAGI recommends that children aged 5 to 11 years should have a 2 dose primary course of the Pfizer COVID-19 vaccine, 8 weeks apart.
This Raising Children article developed in collaboration with MVEC explores the safety, efficacy and recommendations for immunising children aged 5 to 11 years against COVID-19.
要阅读全文，请点击以下链接：
COVID-19 vaccination and children: 5-11 years
澳大利亚免疫技术咨询小组 (ATAGI) 关于使用 Spikevax (Moderna) 作为 COVID-19 加强疫苗的建议
在最近获得 TGA 的批准后， 澳大利亚免疫技术咨询小组 (ATAGI) 已推荐 使用 Spikevax (Moderna) 作为 COVID-19 加强疫苗，适用于 5 个月或更长时间前完成 COVID-19 疫苗初级课程的 18 岁及以上人群（包括孕妇）。加强剂量是用于初级课程的 Spikevax 疫苗推荐剂量的一半。
ATAGI 指出，Moderna 和辉瑞公司的 COVID-19 疫苗在澳大利亚的合格人群中同样可以用作加强疫苗。
To read ATAGI's 关于使用 Moderna COVID-19 疫苗作为加强剂的完整声明如下 下面的链接:
澳大利亚免疫技术咨询小组 (ATAGI) 关于使用 Spikevax (Moderna) 作为 COVID-19 加强疫苗的建议
The Conversation: Is your child frightened of needles? Here’s how to prepare them for their COVID vaccine
Most children are fearful of needles and approximately one in five kids (19%) aged 4-6 years old experience needle phobia.
A child’s initial interaction with needles in their primary years may be formative for their relationship with immunisations throughout their lives. As such, it’s important to cultivate a safe and positive vaccination experience.
This article discusses techniques and strategies to help prepare children for vaccination, including accessing professional help from play and child life therapists for those with needle phobia.
To read the full article, please follow the link below:
Is your child frightened of needles? Here’s how to prepare them for their COVID vaccine
The Conversation: How can scientists update coronavirus vaccines for omicron? A microbiologist answers 5 questions about how Moderna and Pfizer could rapidly adjust mRNA vaccines
The new Omicron variant has raised the question of whether current COVID-19 vaccines will provide sufficient protection against infection. If the virus has changed significantly, antibodies created by the original vaccine will no longer be able to recognise and defend against the new mutated variant. Consequentially, vaccines will need to be modified by swapping out the genetic code of the original spike protein for the one found on the new variant.
This article explores the scientific process behind updating mRNA vaccines including timelines and authorization procedures.
请点击以下链接阅读全文：
Australian Academy of Science: COVID-19 vaccines and their long-term safety
Getting vaccinated against COVID-19 is the best way to protect ourselves and our communities. Current data and evidence confidently support the long term safety of COVID-19 vaccines.
This article discusses the various safety processes currently in place for COVID-19 vaccines to ensure that they continue to be effective in preventing severe disease.
To read the article in full, click on the link below:
COVID-19 vaccines and their long-term safety
The Conversation: COVID vaccines for 5 to 11 year old’s are inching closer. Here’s what we know so far
This week, the US Food and Drug Administration (FDA) has authorised the provisional use of the Pfizer COVID-19 vaccine in children between the age of 5 to 11 years. Children will receive two doses of the vaccine, at a reduced dose (one-third of the adult dose) administered approximately three weeks apart.
Pfizer has submitted a partial application to Australia’s Therapeutic Goods Administration (TGA) and is currently on track to supply the remaining data over the next two weeks. Once approved, the Australian Technical Advisory Group on Immunisations (ATAGI) will advise the government on timing the rollout.
Current data suggests a clear advantage to immunising children against COVID-19, including protecting them from severe complications associated with the Delta variant, and helping to minimise the spread of the virus amongst the more vulnerable in the community.
Follow this link to read the full article:
COVID vaccines for 5 to 11 year old’s are inching closer. Here’s what we know so far
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
Novavax has completed the rolling regulatory submission to the U.K Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of the first protein-based COVID-19 vaccine.
The NVX-CoV2373 vaccine is engineered from the genetic sequence of the first strain of SARS-CoV-2. Using Novavax recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein and is formulated with Novavax patented saponin-based Matrix-M ™ adjuvant to stimulate high levels of neutralizing antibodies.
Clinical data from Phase 3 trials included over 15,000 participants and demonstrated that NVX-CoV2373 elicited a strong immune response with an overall efficacy of 89.7% as well as a favourable safety and tolerability profile.
请点击以下链接阅读全文：
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
MVEC 播客系列 - COVID-19 疫苗
随着 2020 年接近尾声，人们乐观地认为，安全有效的 SARS-CoV-2 (COVID-19) 疫苗将很快获得批准，以控制大流行。目前全球有 200 多种候选疫苗处于临床试验的各个阶段，澳大利亚已与 4 种不同的疫苗签署了预购协议。
在我们的 COVID-19 疫苗 3 部分视频广播系列中，Daryl Cheng 博士和 Daniela Say 博士讨论了如何在如此紧迫的时间内开发疫苗、临床试验中使用的各种疫苗平台及其各自的优缺点，以及要提供免疫接种的不同优先群体。 Daryl 和 Daniela 谈到了临床试验的初步结果以及它们在疫苗安全性和有效性方面向我们展示的内容，并讨论了即使疫苗获准使用也会进行的持续安全监测。
您可以通过以下链接查看播客：
COVID19 疫苗之路的最后一集：Walter Orenstein 教授
在本播客系列的最后一集中，我们的主持人 Nigel Crawford 副教授与 Walter Orenstein 教授进行了交谈。 Orenstein 博士是埃默里大学医学、流行病学、全球健康和儿科学教授；埃默里疫苗中心副主任兼埃默里疫苗政策与开发部主任。 Orenstein 博士是疫苗学专家，曾在美国疾病控制和预防中心工作，担任美国免疫规划署署长，目前是多个 WHO 小组的成员。此外，他还是疫苗教科书 Plotkin's Vaccines 的共同编辑，7日 版。在这一集中，他们讨论了：
- 在 SARS-CoV-2 大流行和疫苗开发的背景下可以从 Plotkin 的疫苗中吸取的教训
- 最近的新闻稿显示了由辉瑞/BioNTech 和 Moderna 开发的两种 mRNA COVID-19 候选疫苗的有希望的早期结果
- 一旦使用疫苗，持续监测疫苗的安全性和有效性的关键作用
- 当疫苗可用时可能最优先的群体
- 儿童在 SARS-CoV-2 传播中的作用以及他们是否需要接种疫苗
- SARS-CoV-2 疫苗保护相关性的重要性
- 需要监测疫苗相关的增强型疾病 (VAED)
- 免疫接种提供者支持免疫接种后不良事件 (AEFI) 报告的重要性
- 沟通在支持疫苗接受和采用方面的重要性
- 研制 COVID-19 疫苗的关键后续步骤：更好地了解需要多少剂量以及何时需要，确定优先次序，以便最有效地使用疫苗（具有明确的分配系统）；并向公众传达社会疏远和戴口罩将持续一段时间，因为不会立即达到正常水平，即使有令人兴奋的新型有效 COVID-19 疫苗
链接：
- 普洛特金的疫苗，7日 编辑
- 辉瑞/BioNTech 完成 COVID-19 候选疫苗的第 3 阶段研究，满足所有主要疗效终点
- Moderna 的 COVID-19 候选疫苗在 3 期 COVE 研究的第一次中期分析中达到了其主要疗效终点
你可以在这里收听这一集：
喇叭 - 苹果 - Spotify 音乐